ZYCUBO® (copper histidinate)
Likely Menkes disease or related copper deficiency disorder (based on drug name)
ApprovedActive
Key Facts
Indication
Likely Menkes disease or related copper deficiency disorder (based on drug name)
Phase
Approved
Status
Active
Company
About Sentynl Therapeutics
Sentynl Therapeutics is a private, commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company has achieved a significant milestone with the FDA approval of ZYCUBO® (copper histidinate), indicating a transition from development to commercialization. Led by a seasoned executive team with extensive experience in specialty pharma startups and product launches, Sentynl operates on guiding principles of impact, innovation, and integrity to address unmet medical needs in niche patient populations.
View full company profile